Invivyd
Logotype for Invivyd Inc

Invivyd (IVVD) investor relations material

Invivyd Study result summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Invivyd Inc
Study result summary29 Sep, 2026

Study design

  • Phase 3 LIBERTY randomized 210 healthy adults aged 18–49 in a double-blind, active-controlled study of VYD2311, an mRNA vaccine, or both; safety assessments covered 6 and 56 days.

  • LIBERTY evaluated safety, tolerability, and immunologic interference; it had no placebo arm and was not designed to establish efficacy.

Safety and tolerability

  • VYD2311 met LIBERTY’s primary and secondary endpoints, showing superior safety and tolerability to the mRNA vaccine.

  • At 6 days, any TEAE, injection-site reaction, or hypersensitivity occurred in 56.5% of VYD2311 recipients versus 91.4% with vaccine (P<0.0001); systemic adverse events occurred in 44.1% versus 68.1% (P=0.008).

  • At 56 days, any TEAE, injection-site reaction, or hypersensitivity occurred in 60.9% of VYD2311 recipients versus 83.1% with vaccine (P<0.0001).

  • No VYD2311-related adverse events exceeded Grade 2, and no hypersensitivity, anaphylaxis, myocarditis, or pericarditis occurred in any arm.

  • Combination dosing was associated with fewer systemic events than vaccine alone, suggesting improved vaccine tolerability.

Immunogenicity

  • Co-administration increased total neutralizing titers by ~2.5x versus vaccine alone, with no evidence of immunologic interference.

  • After VYD2311 was selectively removed from samples, vaccine-induced neutralization titers matched those in the vaccine-only arm.

  • Monotherapy immunogenicity findings were preliminary and underpowered; further review alongside DECLARATION data was anticipated.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Invivyd earnings date

Logotype for Invivyd Inc
Q3 202612 Nov, 2026
Invivyd
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Invivyd earnings date

Logotype for Invivyd Inc
Q3 202612 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Invivyd Inc., a clinical-stage biopharmaceutical company, is focused to the discovery, development, and commercialization of antibody-based solutions targeting infectious diseases, with a primary focus on the United States. The company's mission centers on delivering antibody-based therapies to protect vulnerable populations against circulating viral threats, such as SARS-CoV-2, leveraging advanced antibody engineering and viral surveillance techniques. Invivyd's lead product candidate, adintrevimab, is a neutralizing antibody undergoing clinical trials for both treatment and prevention of coronavirus disease. Additionally, the company is developing monoclonal antibody candidates, including VYD222 and VYD224, aimed at offering neutralizing protection against SARS-CoV-2, alongside discovery stage candidates for seasonal influenza prevention. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.